D-Index & Metrics Best Publications

Hermann Einsele

University of Würzburg
Germany

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name Citations Publications World Ranking National Ranking

Medicine D-index 114 Citations 47,203 931 World Ranking 2733 National Ranking 122

Overview

What is he best known for?

The fields of study Hermann Einsele is best known for:

Cancer
Immune system
Chemotherapy

Many of his Multiple myeloma research pursuits overlap with Lenalidomide and Bortezomib. Hermann Einsele undertakes interdisciplinary study in the fields of Lenalidomide and Multiple myeloma through his research. He performs multidisciplinary study in the fields of Internal medicine and Pathology via his papers. Hermann Einsele applies his multidisciplinary studies on Pathology and Internal medicine in his research. He applies his multidisciplinary studies on Immunology and Virology in his research. He applies his multidisciplinary studies on Virology and Immunology in his research. His Transplantation study frequently links to other fields, such as Surgery. His research brings together the fields of Transplantation and Surgery. Oncology and Chemotherapy are two areas of study in which he engages in interdisciplinary research.

His most cited work include:

Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective (1361 citations)
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma (1055 citations)
Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody (897 citations)

What are the main themes of his work throughout his whole career to date

A majority of his Internal medicine research is a blend of other scientific areas, such as Oncology, Gastroenterology and Surgery. Gastroenterology and Internal medicine are two areas of study in which he engages in interdisciplinary work. His Surgery study frequently links to other fields, such as Transplantation. His Transplantation study frequently draws connections to adjacent fields such as Hematopoietic stem cell transplantation. His Biochemistry study frequently draws parallels with other fields, such as Gene and In vitro. Gene and Genetics are two areas of study in which he engages in interdisciplinary research. His research combines Stem cell and Genetics. He regularly ties together related areas like Biochemistry in his In vitro studies. In his research, Hermann Einsele performs multidisciplinary study on Immunology and Virus.

Hermann Einsele most often published in these fields:

Internal medicine (69.77%)
Immunology (58.50%)
Multiple myeloma (32.92%)

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

Marcie Tomblyn;Tom Chiller;Hermann Einsele;Ronald Gress.
Biology of Blood and Marrow Transplantation (2009)

1946 Citations

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

Abstr Act;Sagar Lonial;Meletios Dimopoulos;Antonio Palumbo.
The New England Journal of Medicine (2015)

1318 Citations

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

Max S. Topp;Peter Kufer;Nicola Gökbuget;Mariele Goebeler.
Journal of Clinical Oncology (2011)

1164 Citations

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody

Ralf Bargou;Eugen Leo;Gerhard Zugmaier;Matthias Klinger.
Science (2008)

1125 Citations

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

Jesús F. San-Miguel;Vânia T.M. Hungria;Sung Soo Yoon;Meral Beksac.
Lancet Oncology (2014)

922 Citations

Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy.

Hermann Einsele;Eddy Roosnek;Nathalie Rufer;Christian Sinzger.
Blood (2002)

871 Citations

The landscape of genomic alterations across childhood cancers

Susanne N. Gröbner;Barbara C. Worst;Joachim Weischenfeldt;Joachim Weischenfeldt;Ivo Buchhalter.
Nature (2018)

840 Citations

Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer

Volker Heinemann;Detlef Quietzsch;Frank Gieseler;Michael Gonnermann.
Journal of Clinical Oncology (2006)

821 Citations

Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial

Jürgen Finke;Wolfgang A Bethge;Claudia Schmoor;Hellmut D Ottinger.
Lancet Oncology (2009)

777 Citations

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

Pieter Sonneveld;Hervé Avet-Loiseau;Sagar Lonial;Saad Usmani.
Blood (2016)

721 Citations

If you think any of the details on this page are incorrect, let us know.